Issue 7, 2010

Areneruthenium complexes as anticancer agents

Abstract

Neutral or cationic arene ruthenium complexes providing both hydrophilic as well as hydrophobic properties due to the robustness of the rutheniumarene unit hold a high potential for the development of metal-based anticancer drugs. Mononuclear arene ruthenium complexes containing P- or N-donor ligands or N,N-, N,O- or O,O-chelating ligands, dinuclear arene ruthenium systems with adjustable organic linkers, trinuclear arene ruthenium clusters containing an oxo cap, tetranuclear arene ruthenium porphyrin derivatives that are photoactive, as well as hexanuclear ruthenium cages that are either empty or filled with other molecules have been shown to be active against a variety of cancer cells.

Graphical abstract: Arene ruthenium complexes as anticancer agents

Article information

Article type
Perspective
Submitted
14 Aug 2009
Accepted
23 Sep 2009
First published
23 Oct 2009

Dalton Trans., 2010,39, 1673-1688

Arene ruthenium complexes as anticancer agents

G. Süss-Fink, Dalton Trans., 2010, 39, 1673 DOI: 10.1039/B916860P

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements